After a long lull on the targeted therapies front – outside of EGFR T790M in lung cancer – this year’s ASCO has plenty to be cheerful about with new data across multiple tumour types. We can’t cover them all here, but more will be discussed in the Daily Live Blogs starting on Saturday.
Which drugs are going to be in roaring back after a quiet period? Which ones will be having a more muted meeting?
For those of you who are working in the targeting therapy world, take heart, there is a future beyond cancer immunotherapy; it is not the universal panacea and will likely not cure every cancer, at least for now.
There’s still a market opportunity for targeted therapies in cancer, and as we mentioned in yesterday’s ASCO Preview, there is also potential for the combination of targeted therapies with immunotherapies, so long as the combined toxicity is manageable and doesn’t outweigh the benefits.
In this post we’re looking at a selection of targeted therapies in a variety of tumour types. There’s a lot to choose from at ASCO this year.
Here’s a few we think are worth highlighting upfront.
Subscribers can log-in to learn more or you can click on the Blue Box below to sign-up and become a member of the burgeoning BSB Community who appreciate the value of education, information and, even occasionally, infotainment…
Next week the Cancer Conference circuit moves on to a double-header with the AACR-NCI-EORTC Molecular Targets & Cancer Therapeutics meeting (Twitter #Targets15) taking place in Boston from November 5 – 9th, and the annual meeting of the Society for Immunotherapy of Cancer (SITC) taking place in National Harbor, MD from November 4 – 8th.
It is unfortunate that the two meetings clash, Molecular Targets is slightly later in the year than it was in 2013 when it was last in Boston. Both focus on the hottest topic in cancer drug development, which will come as no surprise… cancer immunotherapy.
In addition, in Boston there are some posters of note on other novel targets and approaches. Talking of which, Episode 7 of our Novel Targets podcast from the European Cancer Congress is now live. Do listen!
For this preview of #Targets15, we’ve taken a look at the abstracts that were published online yesterday afternoon (the late breakers and those in the press program are not available yet), and highlighted a few of interest, together with a few sessions of note. If you have plans to be in Boston for the conference, this post will be of interest to you.
Subscribers can login to read more below or you can purchase access.
As a heads-up, we will be at the forthcoming American Society of Hematology (ASH) annual meeting in Orlando (Twitter #ASH15), so if you have been sitting on the fence about buying a quarterly subscription, now is a great time to take the leap and join all those folks who want the “real edge” in cancer research.
You’ll obtain all the coverage we have planned over the next 3 months… Check it out!
Beyond the late breaking abstracts and plenary sessions at the European Cancer Conference being held in Vienna, Austria later this month, what other important topics can we expect to hear about?
We covered the former in the last article on Biotech Strategy Blog, today we turn our attention to the proffered (oral) sessions and what we can learn from those sessions and the expected data that is due to be presented.
There are a number of interesting topics and new data slated for presentation that are worthy of review and highlighting in a What To Watch out For (W2W4) format.
Here’s our take on the potential highlights at the meeting.
Subscribers can log in or you can sign up in the box below to learn more about the forthcoming ECCO conference.
As the weather heats up in the western hemisphere, the temperatures are not the only thing increasing…
In Pharmaland, the oncology space traditionally sees either interesting new data published or a spate of post American Society of Clinical Oncology (ASCO) filings. The summer doldrums often give way to a faster pace in the fall.
One thing we have been following over the last two years is the T790M race to market in EGFR mutant lung cancer. Clovis Oncology announced last week that they have begun their rolling NDA submission for rociletinib (CO–1686), but what about their keen rival, AstraZeneca with AZD9291?
The company presented new data for AZD9291 jn the EGFR mutant lung cancer upfront setting, but no formal announcement was made about the regulatory status.
There are some potentially interesting new developments to report here, though.
To learn more about what’s happening, subscribers can sign in below or interested folks can sign up in the box.
The potential of Clovis Oncology’s EGFR inhibitor rociletinib (formerly CO-1686) to treat T790M negative non-small cell lung cancer (NSCLC) was one of the interesting talking points of the recent JP Morgan Healthcare conference in San Francisco (JPM15).
At the JP Morgan Healthcare Conference (JPM15), Clovis presented updated data that shows some efficacy in those NSCLC patients who no longer respond to an EGFR inhibitor, but don’t have a T790M mutation (T790M negative). Both AstraZeneca’s competitor compound, AZD9291, and rociletinib shown considerable activity in those EFGR resistant patients who develop a T790M mutation and it’s likely they will both soon be approved in this indication, based on the encouraging data seen to date.
However, what is surprising and could be a key differentiation factor for Clovis, is if there is sufficient efficacy in T790M negative patients for use of the drug in this indication.
In this post, we discuss the potential of rociletinib in NSCLC T790M negative patients, whether thought leaders might use the drug in this indication, and delve deeper into the science behind the efficacy seen.
Subscribers can login to read more about what this means for the market opportunity for rociletinib. If you are not already a subscriber you can purchase access by clicking on the blue icon at the end of the post.
The embargoed press release and abstract for Clovis’s CO–1686 (rociletinib) in advanced lung cancer patients with and without the T790M mutation, originally scheduled for Friday morning in Barcelona, was released last night. The actual presentation is slated for Friday, November 21 during the Plenary session from 11:00 to 13:00 CET.
Thus the ongoing race to market in this segment continues apace, as do the fairly robust and determined discussions on the topic. Without much further ado to read more about our quick insights and reactions to the data, you can sign up or sign in below.